See the DrugPatentWatch profile for nalmefene
Intranasal nalmefene, marketed as Opvee, received FDA approval on April 5, 2024, for the emergency treatment of opioid overdose [1]. The prescription medication is approved for individuals aged 12 years and older [1].
How does Opvee work?
Opvee is a short-acting opioid antagonist [1]. It works by blocking the effects of opioids on the brain, reversing respiratory depression and other life-threatening symptoms of an overdose [1].
What is the prescription cost for Opvee?
As of its approval, specific pricing details for Opvee have not been widely publicized, but it is available by prescription. Information regarding insurance coverage and patient assistance programs is typically provided by the manufacturer and pharmacies [2].
When does Opvee's patent expire?
Patent information for nalmefene, the active ingredient in Opvee, can be complex and may involve multiple patents covering different aspects of the drug, formulation, and manufacturing processes. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and can provide detailed information on patent expiry dates for various drugs and their formulations [3].
How does nalmefene compare to other overdose reversal medications?
Naloxone is the most widely known opioid antagonist used for overdose reversal, available in multiple forms including nasal sprays (e.g., Narcan) and injectable solutions [4]. Nalmefene, the active ingredient in Opvee, is also an opioid antagonist with a similar mechanism of action [1]. The intranasal formulation of nalmefene offers a needle-free option for emergency overdose treatment [1].
What are the potential side effects of Opvee?
The most common side effects associated with nalmefene include nasal discomfort, headache, nausea, diarrhea, dizziness, and vomiting [1]. In individuals who are physically dependent on opioids, nalmefene can cause sudden and severe withdrawal symptoms [1].
Who manufactures Opvee?
Opvee is manufactured by Opiant Pharmaceuticals [1].
What is the regulatory status of Opvee in other regions?
Information on the regulatory status of Opvee outside of the United States is not detailed in the provided context. Regulatory approvals and availability vary by country [1].
Where can I find more information on nalmefene patents?
DrugPatentWatch.com provides comprehensive data on drug patents, including those related to nalmefene and its formulations. This resource can help determine patent expiry timelines and potential for generic or biosimilar competition [3].
What are the clinical trial results supporting Opvee's approval?
The FDA's approval of Opvee was based on clinical studies demonstrating its effectiveness in reversing opioid-induced respiratory depression [1]. Specific details of these trials, including efficacy and safety data, were reviewed by the agency [1].
What are the challenges in opioid overdose reversal?
Challenges in opioid overdose reversal include timely access to medication, adequate training for administration, and overcoming barriers to treatment, such as stigma and cost [1][4]. Ensuring that bystanders and individuals at risk have access to and know how to use overdose reversal medications is crucial [4].
Sources:
1. https://www.fda.gov/drugs/drug-approvals/fda-approves-first-nasal-nalmefene-product-emergency-treatment-opioid-overdose
2. Information regarding specific prescription costs and insurance coverage for newly approved medications is typically released by the manufacturer and pharmacy benefit managers following FDA approval.
3. https://drugpatentwatch.com/
4. https://www.drugabuse.gov/about-drug-abuse-drug-research/standard-disclaimers